Proactive Investors - Run By Investors For Investors

PhagoMed Biopharma uses technology to find alternative to antibiotics

PhagoMed Biopharma GmbH CEO Alexander Belcredi sat down with Christine Corrado with Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.
The privately-held biotech specializes in developing therapeutics uses for phage therapy, which uses lytic bacteriophages, a virus that infects bacteria, to treat multi-drug resistant bacterial infections.


Meet Rockfire Resources PLC, Touchstone Exploration Inc, Mkango Resources Ltd and Salt Lake Potash Ltd at our event, London , 20 June 2019. Register here »
View full PHAGO profile View Profile

PhagoMed Biopharma Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use